Biopharmaceutical company Kintara Therapeutics Inc (Nasdaq: KTRA) announced on Monday that it has commenced a 15-patient clinical trial for REM-001 in cutaneous metastatic breast cancer (CMBC) patients.
The study aims to confirm the planned dose and optimise the trial design, paving the way for a Phase 3 clinical trial initiation.
REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, will be evaluated for its efficacy, with the primary endpoint being the Best Overall Objective Response Rate (bORR).
Kintara's dedication to developing novel cancer therapies aligns with its REM-001 Therapy program, addressing unmet medical needs in patients.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation